Yunqin Chen1, Jibin Dong2, Xiaojin Zhang3, Xueying Chen4, Li Wang5, Haozhu Chen4, Junbo Ge6, Xian-Cheng Jiang7. 1. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. 2. School of Pharmacy, Fudan University, Shanghai, China. 3. Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China. 4. Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. 5. Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. 6. Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: ge.junbo@zs-hospital.sh.cn. 7. Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA; School of Pharmacy, Fudan University, Shanghai, China. Electronic address: XJiang@downstate.edu.
Abstract
BACKGROUND AND AIMS: Cholesteryl ester transfer protein (CETP) inhibitor-mediated induction of HDL-cholesterol has no effect on the protection from cardiovascular disease (CVD). However, the mechanism is still unknown. Data on the effects of this class of drugs on subclasses of HDL are either limited or insufficient. In this study, we investigated the effect of evacetrapib, a CETP inhibitor, on subclasses of HDL in patients with atherosclerotic cardiovascular disease or diabetes. METHODS: Baseline and 3-month post-treatment samples from atorvastatin 40 mg plus evacetrapib 130 mg (n = 70) and atorvastatin 40 mg plus placebo (n = 30) arms were used for this purpose. Four subclasses of HDL (large HDL, medium HDL, small HDL, and preβ-1 HDL) were separated according to their size and quantified by densitometry using a recently developed native polyacrylamide gel electrophoresis (PAGE) system. RESULTS: Relative to placebo, while evacetrapib treatment dramatically increased large HDL and medium HDL subclasses, it significantly reduced small HDL (27%) as well as preβ-1 HDL (36%) particles. Evacetrapib treatment reduced total LDL, but also resulted in polydisperse LDL with LDL particles larger and smaller than the LDL subclasses of the placebo group. CONCLUSION:Evacetrapib reduced preβ-1 HDL and small HDL in patients with ASCVD or diabetes on statin. Preβ-1 HDL and medium HDL are negatively interrelated. The results could give a clue to understand the effect of CETP inhibitors on cardiovascular outcomes.
RCT Entities:
BACKGROUND AND AIMS: Cholesteryl ester transfer protein (CETP) inhibitor-mediated induction of HDL-cholesterol has no effect on the protection from cardiovascular disease (CVD). However, the mechanism is still unknown. Data on the effects of this class of drugs on subclasses of HDL are either limited or insufficient. In this study, we investigated the effect of evacetrapib, a CETP inhibitor, on subclasses of HDL in patients with atherosclerotic cardiovascular disease or diabetes. METHODS: Baseline and 3-month post-treatment samples from atorvastatin 40 mg plus evacetrapib 130 mg (n = 70) and atorvastatin 40 mg plus placebo (n = 30) arms were used for this purpose. Four subclasses of HDL (large HDL, medium HDL, small HDL, and preβ-1 HDL) were separated according to their size and quantified by densitometry using a recently developed native polyacrylamide gel electrophoresis (PAGE) system. RESULTS: Relative to placebo, while evacetrapib treatment dramatically increased large HDL and medium HDL subclasses, it significantly reduced small HDL (27%) as well as preβ-1 HDL (36%) particles. Evacetrapib treatment reduced total LDL, but also resulted in polydisperse LDL with LDL particles larger and smaller than the LDL subclasses of the placebo group. CONCLUSION:Evacetrapib reduced preβ-1 HDL and small HDL in patients with ASCVD or diabetes on statin. Preβ-1 HDL and medium HDL are negatively interrelated. The results could give a clue to understand the effect of CETP inhibitors on cardiovascular outcomes.
Authors: Robert S Rosenson; H Bryan Brewer; M John Chapman; Sergio Fazio; M Mahmood Hussain; Anatol Kontush; Ronald M Krauss; James D Otvos; Alan T Remaley; Ernst J Schaefer Journal: Clin Chem Date: 2011-01-25 Impact factor: 8.327
Authors: S Yamashita; Y Matsuzawa; M Okazaki; H Kako; T Yasugi; H Akioka; K Hirano; S Tarui Journal: Atherosclerosis Date: 1988-03 Impact factor: 5.162
Authors: Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet Journal: Circulation Date: 2012-04-17 Impact factor: 29.690
Authors: Bela F Asztalos; Dorothea Collins; L Adrienne Cupples; Serkalem Demissie; Katalin V Horvath; Hanna E Bloomfield; Sander J Robins; Ernst J Schaefer Journal: Arterioscler Thromb Vasc Biol Date: 2005-08-25 Impact factor: 8.311
Authors: Stephen J Nicholls; Kausik K Ray; Christie M Ballantyne; Lauren A Beacham; Debra L Miller; Giacomo Ruotolo; Steven E Nissen; Jeffrey S Riesmeyer Journal: Atherosclerosis Date: 2017-04-08 Impact factor: 5.162
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Phu T Duong; Ginny L Weibel; Sissel Lund-Katz; George H Rothblat; Michael C Phillips Journal: J Lipid Res Date: 2008-02-05 Impact factor: 5.922